Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director · PRESIDENT AND CEO | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 235,244 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 18,500 · Balance 253,744 Row 2 · 2026-09-15 · Sale · Disposed 18,500 · Balance 235,244 F1: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2030-12-15 | Direct | 488,801 |
Reported balance
After 2026-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Disposed 18,500 · Balance 488,801 F2: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · derivative · entry 13 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 686,087 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,875 | $43.81 | $82,143.75 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 10 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,875 | $2.90 | $5,431.50 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 9 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 4,635 | $44.03 | $204,093.88 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 8 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.88 to $44.32, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 4,635 | $2.90 | $13,426.67 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 7 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 5,023 | $43.52 | $218,609.50 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 6 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 5,023 | $2.90 | $14,550.63 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,195 | $42.35 | $92,949.25 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.88 to $42.74, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 2,195 | $2.90 | $6,358.48 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 3,772 | $41.33 | $155,883.18 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.87 to $41.82, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 3,772 | $2.90 | $10,926.73 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · derivative · entry 11 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 701,712 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · derivative · entry 10 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 703,587 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 100 | $47.65 | $4,765.00 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · nonDerivative · entry 8 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 100 | $2.90 | $289.68 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · nonDerivative · entry 7 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,775 | $46.94 | $83,324.89 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · nonDerivative · entry 6 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,775 | $2.90 | $5,141.82 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · nonDerivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 700 | $47.55 | $33,283.74 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.43 to $47.61, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 700 | $2.90 | $2,027.76 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 14,925 | $46.91 | $700,149.66 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.42 to $47.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 14,925 | $2.90 | $43,234.74 |
DisclosureSEC source: 0001415889-24-029275 · form4-12132024_091242.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · derivative · entry 14 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 719,212 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · derivative · entry 13 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 721,087 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · derivative · entry 12 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 722,962 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,875 | $49.00 | $91,875.00 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 10 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,875 | $2.90 | $5,431.50 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 9 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,875 | $48.76 | $91,425.00 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 8 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,875 | $2.90 | $5,431.50 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 7 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,381 | $48.80 | $67,398.60 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 6 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.59 to $49.27, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,381 | $2.90 | $4,000.48 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 7,665 | $48.18 | $369,329.59 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.59 to $48.58, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 7,665 | $2.90 | $22,203.97 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 6,579 | $47.05 | $309,532.08 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.59 to $47.55, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 6,579 | $2.90 | $19,058.05 |
DisclosureSEC source: 0001415889-24-027840 · form4-11272024_091139.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · derivative · entry 25 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 738,587 Underlying: Class A Common Stock · 7,500 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · derivative · entry 24 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 746,087 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · derivative · entry 23 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 747,962 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · derivative · entry 22 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 749,837 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · derivative · entry 21 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 751,712 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · derivative · entry 20 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,587 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 7,500 | $49.00 | $367,500.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 18 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 7,500 | $2.90 | $21,726.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 17 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,875 | $49.50 | $92,811.00 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 16 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,875 | $2.90 | $5,431.50 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 15 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,875 | $49.52 | $92,848.50 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 14 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,875 | $2.90 | $5,431.50 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 13 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,875 | $49.57 | $92,951.06 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 12 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,875 | $2.90 | $5,431.50 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 11 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 310 | $50.35 | $15,608.81 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 10 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,942 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.13 to $50.78, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 310 | $2.90 | $898.01 |
DisclosureSEC source: 0001415889-24-026944 · form4-11152024_091112.xml · nonDerivative · entry 9 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.